Which groups are not suitable for taking Momelotinib and tips on potential risks

Momelotinib is an oral small molecule inhibitor mainly used to treat myelofibrosis and related hematological diseases. Although it has shown efficacy in improving anemia and controlling symptoms of myelofibrosis, not all patients are suitable for use and need to be evaluated based on medical history, underlying diseases, and individual health status.

First, patients with severe hepatic and renal insufficiency are not suitable for molotinib. Since the drug is mainly metabolized by the liver and partially excreted by the kidneys, impaired liver and kidney function may lead to an increase in blood drug concentration, increase the risk of drug toxicity, and may cause liver damage or severe bone marrow suppression. Therefore, such patients need to have liver and kidney function evaluated before use. If the function is obviously abnormal, alternative treatment or dose adjustment should be considered.

Secondly, patients with severe hematological abnormalities also need to be cautious. Molotinib can cause myelosuppression, manifested by a decrease in neutrophils, platelets, or red blood cells. For patients with very low baseline blood cell counts, use may increase the risk of infection, bleeding, or worsening of anemia. Therefore, doctors usually require that blood routine indicators be assessed before medication and be monitored regularly during treatment. If necessary, the dose should be adjusted or medication suspended to ensure medication safety.

In addition, pregnant and lactating women are not suitable to use molotinib. Animal experiments show that the drug may have adverse effects on the fetus, and use during lactation may affect the health of the baby through milk. Use in these groups requires weighing the pros and cons and selecting safe alternatives under strict medical guidance. Overall, although molotinib has therapeutic advantages, for people with liver and kidney dysfunction, abnormal blood indicators, and special physiological conditions, potential risks should be fully assessed and the principle of individualized medication should be followed to ensure the safety of treatment.

Reference materials:https://www.nlm.nih.gov/